<DOC>
	<DOCNO>NCT00560508</DOCNO>
	<brief_summary>The objective trial investigate safety , tolerability , trough plasma concentration , efficacy pramipexole ER comparison pramipexole IR administrate orally 12 week patient PD levodopa ( L-DOPA ) therapy ( double-blind period ) . The double-blind period follow open-label 52 week administration pramipexole ER evaluate long term safety efficacy ( open-label period ) .</brief_summary>
	<brief_title>A 12-week Study Pramipexole Extended Release ( ER ) Patients With Parkinson 's Disease ( PD ) , Followed 52-week Long-term Treatment Period</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<criteria>Inclusion criterion 1 . Male female patient diagnosis PD include juvenile Parkinsonism , onset begin age forty younger . 2 . Patients modify Hoehn Yahr scale II IV `` '' time . 3 . Patients receive individual dosage LDOPA ( either standard LDOPA LDOPA dopadecarboxylase inhibitor ) stable dose least 4 week baseline visit ( Visit 2 ) . 4 . Patients exhibit therapeutically problematic issue status base LDOPA therapy : wearingoff phenomenon /delayed dystonia time onoff phenomenon freeze phenomena time suboptimal dose LDOPA administer due side effect ( dyskinesia ) , therapeutical strategy Exclusion criteria 1 . Atypical parkinsonian syndrome due drug , metabolic disorder , encephalitis degenerative disease . 2 . Dementia , define MiniMental State Examination ( MMSE ) score &lt; 24 screen visit . 3 . Any psychiatric disorder accord DSMIV criterion could prevent compliance completion trial and/or put patient risk he/she take part trial . 4 . History psychosis , except history drug induce hallucination ( provide investigator considers participation trial would represent significant risk patient ) . 5 . Clinically significant ECG abnormality screen visit , accord investigator 's judgement . 6 . Clinically significant hypotension symptomatic orthostatic hypotension ( i.e. , clinical symptom orthostatic hypotension dizziness postural etc associate decline &gt; =20 mmHg systolic blood pressure decline &gt; =10 mmHg diastolic blood pressure , one minute standing compare previous supine systolic diastolic blood pressure obtain 5 minute quiet rest ) either screen visit baseline visit . 7 . Any clinically significant disease , whether treat , could put patient risk could prevent compliance completion trial . 8 . Pregnancy ( exclude serum pregnancy test screen visit ) breastfeeding . 9 . Sexually active female childbearing potential use medically approve method birth control within one month screen visit throughout trial period . 10 . Serum level AST , ALT , alkaline phosphatase bilirubin &gt; 2 upper limit normal . 11 . Patients creatinine clearance &lt; 50 mL/min 12 . Patients complication sign malignant tumour within 5 year treatment .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>